Korea Brad Edwards became the first foreign general manager in the Lundbeck Korea’s 23-year history last year, joining from a background at Shire and Takeda across Australia and Singapore. He spoke to us about steering the company’s shift from psychiatry toward neuro-rare disease, the upcoming launch of its new migraine treatment,…
Germany Germany is one of Takeda’s largest markets, a major manufacturing base and an important clinical research location, yet its long-standing reputation for rapid access to innovation is coming under pressure. GM Germany Dr Ingeborg Borgheim discusses how Takeda is preparing its German operations for a new generation of launches, where…
Korea Korea, the world’s 13th-largest pharma market, is rolling out its biggest reform to pharma pricing in a generation, slashing what it pays for generics and using the savings to get innovative medicines to patients faster and at better prices. The same squeeze on generic margins, combined with new rewards for…
Europe Michala Fischer-Hansen, EVP and Head of Europe & International Markets at Lundbeck, discusses her return to pharma and Lundbeck’s focused innovator strategy, centred on neuroscience, R&D and growth through regional partnerships. She examines Europe’s evolving pharmaceutical landscape, from patent expiries and pricing pressure to growing attention on brain health, and…
Germany DACH should become a powerhouse for the Group Germany is emerging as a key growth and launch market for Ipsen, with the DACH region now ranking as the Group’s leading European affiliate and gaining momentum across Oncology, Rare Disease and Neuroscience. As Ipsen enters its next phase of growth, new…
Germany Our objective is to navigate ongoing healthcare reforms successfully, serve as a primary growth engine for Viatris in Europe, and maximize our contribution to patient care Simon von Boeselager, Country Manager Germany at Viatris brings extensive experience across pharmaceutical strategy, commercial leadership, and digital health. He highlights Germany’s role as…
Europe Eight years into its shift into rare diseases, Ferrer is moving into a new phase as its pipeline matures. CEO Mario Rovirosa reflects on the setbacks and lessons shaping that journey, as well as the growing pressures on Europe’s ability to sustain innovation and patient access. Throughout, Ferrer’s commitment to…
Korea We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum for the affiliate, driven by its fertility and oncology portfolios, as well as an improved access framework for innovative treatments…
Africa Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up to meet demand? A new report from the Access to Medicine Foundation suggests that they can, but that new market…
Europe Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority development programmes. As the group prepares potential launches in narcolepsy, psoriasis and polycythaemia vera, a rare blood cancer, Gamze Yuceland explains how patient insight,…
Germany Growth in rare diseases is measured differently. It is not simply about launching new products, but about improving diagnosis, strengthening healthcare partnerships, and supporting patients throughout their journey. Those principles are shaping Orphalan’s next chapter, as the company expands beyond its longstanding focus on Wilson disease into new rare diseases.…
Germany Germany is the default first-choice European market for launching new, innovative medicines. But with the country’s pricing system under growing strain from both national and international pressures, some in the industry are asking how long that status can hold. Germany is, by far, Europe’s leading country for fast and…
See our Cookie Privacy Policy Here
